HeartMate 3™ CE Mark Clinical Investigation Plan

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2020-03-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this clinical investigation is to evaluate the performance and safety of the HeartMate 3 Left Ventricular Assist System (HM3 LVAS) To support obtaining CE Mark for the HM3 LVAS in Europe, a multi-center clinical study will be conducted in multiple countries. The clinical study will be conducted in compliance with the Declaration of Helsinki, ICH/GCP and EN ISO 14155:2011 Requirements for Clinical Investigations and in accordance with country-specific requirements, under one clinical study protocol.

This study will evaluate the performance of the HM3 LVAS, side effects and undesirable conditions within acceptable risks and weigh them against the intended performance of HM3 LVAS in accordance with Essential Requirements 2, 5 and 16 of the Active Implantable Medical Device Directive 90/385/EEC (AIMDD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

HeartMate 3 ELEVATE™ Registry

NCT02497950

Heart Failure Cardiovascular Disease Ventricular Dysfunction

COMPLETED

Implantation of the HeartMate 3 in Subjects With Heart Failure Using Surgical SWIFT HM3 PMS

NCT04548128

Advanced Refractory Left Ventricular Heart Failure

COMPLETED

Post Market Surveillance of the HeartMate 3 Left Ventricular Assist System in Korea

NCT04915924

Advanced Heart Failure

COMPLETED NA

Hong Kong and Taiwan HM3 PMS

NCT04703855

Advanced Heart Failure

TERMINATED NA

LVAD Versus GDMT in Ambulatory Advanced Heart Failure Patients

NCT04768322

End-stage Heart Failure

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Refractory Left Ventricular Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HeartMate 3

Left Ventricular Assist System (LVAS) to be used on Subjects with advanced refractory left ventricular heart failure

Group Type EXPERIMENTAL

Left Ventricular Assist System (LVAS)

Intervention Type DEVICE

Implantation of left ventricular assist device for hemodynamic support

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Left Ventricular Assist System (LVAS)

Implantation of left ventricular assist device for hemodynamic support

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient or legal representative has signed Informed Consent Form (ICF)
2. Age ≥ 18 years
3. BSA ≥ 1.2 m2
4. NYHA IIIB or IV OR ACC/AHA Stage D
5. LVEF ≤ 25%
6. CI ≤ 2.2 L/min/m2, while not on inotropes
7. Patients must also meet one of the following:

\- On Optimal Medical Management (OMM), based on current heart failure practice guidelines for at least 45 out of the last 60 days and are failing to respond,

OR

\- In NYHA class IIIB or IV heart failure for at least 14 days AND dependent on intraaortic balloon pump (IABP) for at least 7 days,

OR

\- Inotrope dependent/unable to wean from inotropes

OR

\- Listed for Transplant
8. Females of child bearing age must agree to use adequate contraception

Exclusion Criteria

1. Etiology of HF due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis or restrictive cardiomyopathy
2. Technical obstacles which pose an inordinately high surgical risk, in the judgment of the investigator
3. Existence of ongoing mechanical circulatory support (MCS) other than IABP
4. Positive pregnancy test if of childbearing potential
5. Lactating mothers
6. Presence of mechanical aortic cardiac valve that will not be converted to a bioprosthesis at the time of LVAD implant
7. History of any organ transplant
8. Platelet count \< 100,000 x 103/L (\< 100,000/ml)
9. Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAS management
10. History of confirmed, untreated AAA \> 5 cm in diameter
11. Presence of an active, uncontrolled infection
12. Intolerance to anticoagulant or antiplatelet therapies or any other peri/post-operative therapy the investigator will require based upon the patients' health status
13. Presence of any one of the following risk factors for indications of severe end organ dysfunction or failure:

1. An INR ≥ 2.5 not due to anticoagulation therapy
2. Total bilirubin \> 43 umol/L (2.5 mg/dl), shock liver, or biopsy proven liver cirrhosis
3. History of severe chronic obstructive pulmonary disease (COPD) defined by FEV1/FVC \< 0.7, or FEV1 \<50% predicted
4. Fixed pulmonary hypertension with a most recent PVR ≥ 8 Wood units that is unresponsive to pharmacologic intervention
5. History of stroke within 90 days prior to enrollment, or a history of cerebrovascular disease with significant (\> 80%) carotid artery stenosis
6. Serum creatinine ≥221umol/L (2.5 mg/dl) or the need for chronic renal replacement therapy
7. Significant peripheral vascular disease (PVD) accompanied by rest pain or extremity ulceration
14. Patient has moderate to severe aortic insufficiency without plans for correction during pump implant
15. Pre albumin \< 150 mg/L, or Albumin \< 30g/L (3 g/dL)
16. Planned Bi-VAD support prior to enrollment
17. Patient has known hypo or hyper coagulable states such as disseminated intravascular coagulation and heparin induced thrombocytopenia
18. Participation in any other clinical investigation that is likely to confound study results or affect the study
19. Any condition other than HF that could limit survival to less than 24 months

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No